(3-羟基甲基-苄基)-羧酸叔丁酯 | 226070-69-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-羟基甲基-苄基)-羧酸叔丁酯
• 中文别名: N-Boc-3-(氨甲基)苯甲醇；3-(羟甲基)苄基甲酸叔丁酯
• 英文名称: 1,1-dimethylethyl {[3-(hydroxymethyl)phenyl]methyl}carbamate
• 英文别名: (3-hydroxymethyl-benzyl)-carbamic acid tert-butyl ester；3-tert-butoxycarbonylaminomethylbenzyl alcohol；tert-butyl (3-(hydroxymethyl)benzyl)carbamate；tert-butyl 3-(hydroxymethyl)benzylcarbamate；(3-hydroxymethyl-benzyl)carbamic acid tert-butyl ester；(3-hydroxymethylbenzyl)carbamic acid tert-butyl ester；tert-butyl N-[[3-(hydroxymethyl)phenyl]methyl]carbamate
• CAS: 226070-69-5
• 化学式: C₁₃H₁₉NO₃
• 分子量: 237.299
• InChiKey: QNDFFICIIGQGDV-UHFFFAOYSA-N

物化性质

• 熔点：
  51 °C
• 沸点：
  0°C
• 密度：
  1.106±0.06 g/cm3(Predicted)
• 闪点：
  0°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2924299090
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	(3-Hydroxymethyl-benzyl)-carbamic acid tert-butyl ester Material Safety Data Sheet
Synonym:	none know
CAS:	226070-69-5

Section 1 - Chemical Product MSDS Name:(3-Hydroxymethyl-benzyl)-carbamic acid tert-butyl ester Material Safety Data Sheet
Synonym:none know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
226070-69-5	(3-Hydroxymethyl-benzyl)-carbamic acid	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 226070-69-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 39 - 41 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H19NO3
Molecular Weight: 237.3

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 226070-69-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(3-Hydroxymethyl-benzyl)-carbamic acid tert-butyl ester - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 226070-69-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 226070-69-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 226070-69-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-羟基甲基-苄基)-羧酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 [3-(氨基甲基)苯基]甲醇SALTDATA:HCL
  参考文献：
  名称：

  Azabicycloalkane compounds

  摘要：

  这项发明提供了式I的化合物： 其中R1、R2、R3、R4、R5、R6和R7如规范中所定义，或其药用可接受盐、溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和肌碱受体拮抗剂活性。这些化合物对治疗肺部疾病，如慢性阻塞性肺病和哮喘，是有用的。

  公开号：

  US20040242622A1
• 作为产物：
  描述：

  间甲基苯甲酸 在 偶氮二异丁腈 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 dimethyl sulfide borane 、 水 、 碳酸氢钠 、 一水合肼 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.17h， 生成 (3-羟基甲基-苄基)-羧酸叔丁酯
  参考文献：
  名称：

  [EN] HISTONE DEACETYLASE INHIBITORS
  [FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE

  摘要：

  该披露提供了I式化合物及其制备方法。这些化合物作为组蛋白去乙酰化酶的抑制剂。

  公开号：

  WO2011021209A1

文献信息

• IMIDAZOLE CARBOXAMIDES
  申请人：Khilevich Albert

  公开号：US20100016373A1

  公开（公告）日：2010-01-21

  The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

  本发明提供了某些咪唑羧酰胺衍生物，其药物组合物，使用方法以及制备方法。
• Multicyclic bis-amide MMP inhibitors
  申请人：Powers Timothy

  公开号：US20060173183A1

  公开（公告）日：2006-08-03

  The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
  申请人：SENOMYX, INC.

  公开号：US09247759B2

  公开（公告）日：2016-02-02

  The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.

  本发明涉及发现，T2R味觉受体家族中的特定人类味觉受体对存在于咖啡等物质中的特定苦味化合物产生反应。此外，本发明涉及发现特定化合物和含有该化合物的组合物，其作为苦味阻断剂的功能，以及将其用作苦味阻断剂或调味剂，例如在咖啡和咖啡味食品、饮料和药品中。此外，本发明涉及发现一种对多种不同人类T2R产生拮抗作用的化合物，以及将其用于检测中和作为人类和动物摄入的组合物中的苦味阻断剂。
• Synthesis and Structure–Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists
  作者：Panayiotis A. Procopiou、John W. Barrett、Nicholas P. Barton、Malcolm Begg、David Clapham、Royston C. B. Copley、Alison J. Ford、Rebecca H. Graves、David A. Hall、Ashley P. Hancock、Alan P. Hill、Heather Hobbs、Simon T. Hodgson、Coline Jumeaux、Yannick M. L. Lacroix、Afjal H. Miah、Karen M. L. Morriss、Deborah Needham、Emma B. Sheriff、Robert J. Slack、Claire E. Smith、Steven L. Sollis、Hugo Staton

  DOI：10.1021/jm301572h

  日期：2013.3.14

  substituents. Only small groups were tolerated at C5, C6, or C7, with the C6 analogues being preferred. The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide. N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]– group were the most potent N1-substituents. Strongly basic amino groups had low oral absorption in vivo. Less basic analogues, such as morpholines, had good oral

  合成了一系列吲唑芳基磺酰胺，并作为人CCR4拮抗剂进行了研究。含甲氧基或羟基的是更有效的吲唑C4取代基。在C5，C6或C7处只容忍少数人，优选C6类似物。最有效的N 3取代基是5-氯噻吩-2-磺酰胺。具有α-氨基-3-[（甲基氨基）酰基]-基团的N 1间位取代的苄基是最有效的N 1取代基。强碱性氨基在体内的口服吸收率低。诸如吗啉之类的碱性较低的类似物具有良好的口服吸收。但是，它们的间隙也很高。在两个物种中吸收最强的化合物是类似物6（GSK2239633A），已被选择进行进一步开发。芳基磺酰胺拮抗剂在表示为位点II的细胞内变构位点结合CCR4。对两个吲唑磺酰胺片段的X射线衍射研究表明，在活性构象中存在重要的分子内相互作用。